Lexaria Incorporates New Subsidiary for CPG Products and Updates Human Nicotine Study
KELOWNA, BC / ACCESSWIRE / July 28, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces it has incorporated a new wholly-owned…
Lexaria Biotech: An Undervalued Growth Opportunity
Last month, we highlighted Lexaria Bioscience Corp. (Nasdaq: LEXX) as a biotech company that was trading at a discount and wanted to issue an update after it made several important…
Lexaria Discovers that DehydraTECH-CBD Treatment in Hypertension Study HYPER-H21-4 Resulted in Reduction in Pro-Inflammatory Biomarkers
KELOWNA, BC / ACCESSWIRE / May 23, 2023 / Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms is pleased to announce additional findings from…
Lexaria Awards CRO Contract for Upcoming U.S. Phase 1b Hypertension Study
KELOWNA, BC / ACCESSWIRE / April 24, 2023 / Lexaria Bioscience Corp. (Nasdaq:LEXX)(Nasdaq:LEXXW) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms announces it has awarded the contract for…
Lexaria Biosciences: An Undervalued Biotech Opportunity
When analyzing biotech companies, positive clinical trial results are the most significant potential catalyst for businesses. For this reason, we are favorable on companies that have been reporting positive results…
Lexaria Bioscience: A Misunderstood Growth Story
During the last week, Lexaria Bioscience (Nasdaq: LEXX) has come under pressure and we believe the pullback has created a great opportunity for investors. The biotech company has been nothing…
CEO Spotlight: Lexaria Bioscience
Today, we are lucky to have Lexaria Bioscience CEO Chris Bunka with us. During the last year, the biotech company has reported a series of positive developments and we are…
Lexaria Bioscience: A Deep Dive
Earlier this year, we published a business opportunity report on Lexaria Bioscience Corp. (Nasdaq: LEXX) (Nasdaq: LEXXW) and believe the company is flying under the radar. The biotech company operates…
